Payments either by check, bank transfer or paypal.
My first name: dirk; my last name: haussecker
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
7 comments:
Dirk, if I were to order a copy would I get to read about endosomal escape hatch technology? And who it is that is blazing a trail in this area?
I'm afraid not really.
Dirk, you should help Marina Biotech discover a polymer delivery system so they could be the one stop shop for oligo therapeutics!
It is time for a new poll for 2014...
Well, the answer would be already known for that...Sanofi/Genzyme.
I hope this one is on your list.
BLT's ddRNAi coming in to play yet again.
Gene therapy biopharma uniQure sets terms for $64 million IPO
1/24/14
uniQure, which develops gene therapies for the treatment of orphan diseases, announced terms for its IPO on Friday. The Amsterdam, Netherlands-based company plans to raise $64 million by offering 4.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, uniQure would command a market value of $235 million.
uniQure, which was founded in 1998 and booked $3 million in license and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. uniQure initially filed confidentially on November 8, 2013. Jefferies, Leerink Partners and Piper Jaffray are the joint bookrunners on the deal
Thanks for the Guide
Post a Comment